Jobs

Part-time considered (minimum 22.5 hours per week)


Salary range £35k-£45k pro rata


One Nucleus, the Cambridge headquartered membership organisation for life science companies is now recruiting for a Member Engagement Manager to work within the Business Development team to deliver member support, events and sector reports.


Role:


Working as part of the team to meet the collective Business Development goals including to :

About The Company

IONTAS is a pioneering and internationally renowned company focused on biotherapeutic drug development. Co-founded by John McCafferty, an inventor of antibody phage display technology, IONTAS combines deep expertise in antibody phage display with a cutting-edge proprietary mammalian display platform capable of identifying high affinity and developable lead antibody candidates during the earliest stages of drug discovery. This exciting set of technologies and expertise gives the company a unique edge in therapeutic antibody development.

About The Company

IONTAS is a pioneering and internationally renowned company focused on biotherapeutic drug development. Co-founded by John McCafferty, an inventor of antibody phage display technology, IONTAS combines deep expertise in antibody phage display with a cutting-edge proprietary mammalian display platform capable of identifying high affinity and developable lead antibody candidates during the earliest stages of drug discovery. This exciting set of technologies and expertise gives the company a unique edge in therapeutic antibody development.

About The Company

IONTAS is a pioneering and internationally renowned company focused on biotherapeutic drug development. Co-founded by John McCafferty, an inventor of antibody phage display technology, IONTAS combines deep expertise in antibody phage display with a cutting-edge proprietary mammalian display platform capable of identifying high affinity and developable lead antibody candidates during the earliest stages of drug discovery. This exciting set of technologies and expertise gives the company a unique edge in therapeutic antibody development.

Have you got a passion for early-stage drug discovery?


Would you like to lead an experienced multi-disciplinary team?


Are you looking to work for a company that really cares about it’s employees?


A rapidly growing, Glasgow-based drug discovery company are looking to build and expand their medicinal chemistry team. They’ve built strong long-term relationships with their clients, and currently work with some of the top biotech and pharma companies developing drugs that will influence the lives of numerous people.

Have you got a passion for early-stage drug discovery?


Would you like to lead an experienced multi-disciplinary team?


Are you looking to work for a company that really cares about it’s employees?


A rapidly growing, Glasgow-based drug discovery company are looking to build and expand their medicinal chemistry team. They’ve built strong long-term relationships with their clients, and currently work with some of the top biotech and pharma companies developing drugs that will influence the lives of numerous people.

Isomerase is an innovative, growing biotechnology company based at Chesterford Research Park near Cambridge, UK. It was founded in 2012 and has particular expertise in synthetic biology, bioengineering and the discovery and development of the next generation of microbial natural products, proteins and peptides for use in areas such as medicine, agritech or sustainable alternatives to existing petroleum based products.

We are looking for excellent candidates able to work in a multidisciplinary team generating technologies and solving problems on the chemistry/biology interface.

We are looking for two driven individuals to join us as Lead Manufacturing Biotechnologists.


We are RoslinCT, a world-leading cell and gene therapy contract development and manufacturing organisation creating cutting-edge therapies that change people’s lives. Collaborative, dedicated and talented people are at the backbone of our culture, working both autonomously and in driven teams to make life-changing products utilising ground-breaking science.

A BIT ABOUT US…

At F-star, we are dedicated to developing next generation immunotherapies to transform the lives of patients with cancer. We develop mAb², a novel class of disruptive bispecific antibody-based therapies that have the potential to overcome tumour resistance and restore anti-cancer immunity and responsiveness.

We are committed to delivering life-changing treatments for the estimated 80% of patients with cancer who currently fail to have a durable response to immunotherapies.

A BIT ABOUT US…

At F-star, we are dedicated to developing next generation immunotherapies to transform the lives of patients with cancer. We develop mAb², a novel class of disruptive bispecific antibody-based therapies that have the potential to overcome tumor resistance and restore anti-cancer immunity and responsiveness.

We are committed to delivering life-changing treatments for the estimated 80% of patients with cancer who currently fail to have a durable response to immunotherapies.

Pages